Author(s): Dahm M, Lotz J, Hafner G, Oelert H, Prellwitz W
Abstract Share this page
Abstract In a prospective study, 39 patients following aortic or mitral valve replacement underwent investigation of molecular markers (prothrombin fragment F1+2, Factor II) in the initial phase of oral anticoagulation therapy (OAT). The results demonstrate that, despite INR being in the depicted range, the levels of the molecular markers remained high, indicating an increased risk of thromboembolic events. This leads to the conclusion that molecular markers are superior to INR in the monitoring of the early phase of OAT.
This article was published in Z Kardiol
and referenced in Journal of Clinical Case Reports